RU94024566A - Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики - Google Patents

Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики

Info

Publication number
RU94024566A
RU94024566A RU94024566/14A RU94024566A RU94024566A RU 94024566 A RU94024566 A RU 94024566A RU 94024566/14 A RU94024566/14 A RU 94024566/14A RU 94024566 A RU94024566 A RU 94024566A RU 94024566 A RU94024566 A RU 94024566A
Authority
RU
Russia
Prior art keywords
protein
modified proteins
antibody
pharmaceutical compositions
diagnosis
Prior art date
Application number
RU94024566/14A
Other languages
English (en)
Other versions
RU2157239C2 (ru
Inventor
Мэлфрой-Кэмин Бернард
Us]
Original Assignee
Юкэрион
Юкэрион, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юкэрион, Юкэрион, Инк., Инк. (US) filed Critical Юкэрион
Publication of RU94024566A publication Critical patent/RU94024566A/ru
Application granted granted Critical
Publication of RU2157239C2 publication Critical patent/RU2157239C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение обеспечивает способы нацеливания белка, такого как антитело, во внутриклеточные компартменты эукариотической клетки, способы усиления поглощения органами белков, фармацевтические композиции модифицированных белков для лечения человека и способы приготовления модифицированных белков. Модифицированные белки изобретения включают связанный с липидом белок, в котором одна или более ацильных групп связаны с белком посредством боковой углеводной цепи и различными ковалентными связями. Липидизированные антитела могут применяться в лечебных и диагностических целях.

Claims (1)

  1. Изобретение обеспечивает способы нацеливания белка, такого как антитело, во внутриклеточные компартменты эукариотической клетки, способы усиления поглощения органами белков, фармацевтические композиции модифицированных белков для лечения человека и способы приготовления модифицированных белков. Модифицированные белки изобретения включают связанный с липидом белок, в котором одна или более ацильных групп связаны с белком посредством боковой углеводной цепи и различными ковалентными связями. Липидизированные антитела могут применяться в лечебных и диагностических целях.
RU94024566/14A 1992-07-13 1993-07-13 Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики RU2157239C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91245392A 1992-07-13 1992-07-13
US07/912,453 1992-07-13
US07/912.453 1992-07-13

Publications (2)

Publication Number Publication Date
RU94024566A true RU94024566A (ru) 1996-09-27
RU2157239C2 RU2157239C2 (ru) 2000-10-10

Family

ID=25431949

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94024566/14A RU2157239C2 (ru) 1992-07-13 1993-07-13 Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики

Country Status (10)

Country Link
EP (1) EP0607408A4 (ru)
JP (1) JPH07502753A (ru)
KR (2) KR20030097604A (ru)
AU (1) AU4772793A (ru)
CA (1) CA2118586A1 (ru)
FI (1) FI941169A (ru)
NZ (1) NZ255043A (ru)
OA (1) OA09893A (ru)
RU (1) RU2157239C2 (ru)
WO (1) WO1994001131A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JPH11510489A (ja) * 1995-07-21 1999-09-14 ジンタ・インコーポレイテッド 新規アミド基本カチオン性脂質
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
CA2472927A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
JP4381822B2 (ja) * 2002-03-22 2009-12-09 株式会社バイファ 免疫グロブリン親水性ペプチド複合体
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
AU2007227592B2 (en) * 2006-03-16 2011-11-24 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
KR20170061720A (ko) 2006-10-12 2017-06-05 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
AU2007316597B2 (en) 2006-11-07 2013-01-31 Katholieke Universiteit Leuven, K. U. Leuven R & D Diagnosis and treatment of T-cell acute lymphoblastic leukemia
EP2096121A1 (en) * 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US20130149297A1 (en) 2010-07-02 2013-06-13 Vib Vzw Role of fragile x mental retardation gene and protein in cancer metastasis
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2012307159A1 (en) 2011-09-14 2014-02-27 Abeterno Technologies Limited Intracellular cell selection
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
GB201306589D0 (en) 2013-04-11 2013-05-29 Abeterno Ltd Live cell imaging
EA201690492A1 (ru) 2013-08-29 2016-08-31 Сити Оф Хоуп Проникающие в клетку конъюгаты и способы их применения
KR101470793B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 흡수촉진제로서의 펩타이드와 이를 포함하는 조성물
JP2020523035A (ja) 2017-06-07 2020-08-06 エーディーアールエックス， インコーポレイテッド タウ凝集阻害剤
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
EP0306912A3 (en) * 1987-09-08 1989-07-05 Albany Medical College Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
JPH04503957A (ja) * 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
DE69026380T2 (de) * 1989-06-23 1996-10-17 The Liposome Co.,Inc., Princeton, N.J. Zielliposomen und verfahren zur kupplung von liposomen-proteinen
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same

Also Published As

Publication number Publication date
CA2118586A1 (en) 1994-01-20
JPH07502753A (ja) 1995-03-23
FI941169A0 (fi) 1994-03-11
FI941169A (fi) 1994-05-04
AU4772793A (en) 1994-01-31
NZ255043A (en) 1997-03-24
OA09893A (en) 1994-09-15
KR100372119B1 (ko) 2003-06-28
WO1994001131A1 (en) 1994-01-20
EP0607408A4 (en) 1997-12-10
RU2157239C2 (ru) 2000-10-10
EP0607408A1 (en) 1994-07-27
KR20030097604A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
RU94024566A (ru) Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
Forester et al. Characteristics of a high molecular weight extracellular protein of Streptococcus mutans
DE69835438T2 (de) Photo-empfindlichkeit-erhöhende konjugate zur targeting von pathogene
DE3853740T2 (de) Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
DK0730608T3 (da) Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
DK499086D0 (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
ATE279946T1 (de) Herstellung und verwendung von immunkonjugaten die eine vl-kette enthalten welche am asn in position 18 glykosyliert ist
EA199700359A1 (ru) Пептиды и соединения, связывающиеся с тромбопоэтиновым рецептором
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
DK1246826T3 (da) Chlorophyl- og bakteriochlorophylestere, deres fremstilling og farmaceutiske præparater omfattende disse estere
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
GB8824869D0 (en) Synthetic antibody
ZA94446B (en) Use of monoclonal anti-lfa-1 antibodies for the prepartion of a drug to prevent the rejection of solid organ transplants and drugs obtained
ATE131471T1 (de) An fette gebundene aminosäuren, peptide oder deren derivate
Wilkinson Inhibition of leukocyte locomotion and chemotaxis by lipid-specific bacterial toxins
ES2144054T3 (es) Complejos de tri(platino).
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
ATE191852T1 (de) Photodynamische konjugate mit biozide eigenschaften
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
Molina et al. Regulation of macrophage activation markers by IL-4 and IFN-γ is subpopulation-specific
WAGNER et al. Histochemical studies in cystic fibrosis of the pancreas

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20030714